ÂÜÀòÂÒÂ×

Reinhard Pell is an accomplished professional in analytical development, currently serving as VP of Analytical Development at Valneva since September 2024 and as Founder & Chairman of Cure MCOPS12. Previously, Reinhard held various leadership roles at Bayer from October 2020 to August 2024, including VP and Head of Analytical Development API, and at Sandoz from September 2018 to September 2020 as Head of Analytical Development. Reinhard's extensive experience includes key positions at Novartis as an Analytical Expert, DSM as a QC Chemist, and a brief tenure as a Visiting Research Scientist at AstraZeneca. Reinhard holds a PhD in Analytical Chemistry and a Magister der Naturwissenschaften from the University of Vienna, complemented by studies at Lund University.